Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1991;17:733-741

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossman, E.
Right arrow Articles by Keiser, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossman, E.
Right arrow Articles by Keiser, H. R.

Hypertension, Vol 17, 733-741, Copyright © 1991 by American Heart Association


ARTICLES

Glucagon and clonidine testing in the diagnosis of pheochromocytoma

E Grossman, DS Goldstein, A Hoffman and HR Keiser
Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

We assessed the sensitivity and specificity of glucagon stimulation and clonidine suppression tests in the diagnosis of pheochromocytoma in 113 hypertensive patients, 39 with and 74 without the tumor. In the glucagon stimulation test, blood was sampled 2 minutes after intravenous injection of 0.28 mumol (1 mg) glucagon, and in the clonidine suppression test, blood was sampled 3 hours after administration of oral clonidine, 1.30 mumol (0.3 mg)/70 kg body wt. Baseline levels of catechols in antecubital venous blood were abnormal, with norepinephrine greater than 7.10 nmol/l (1,200 pg/m), epinephrine greater than 1.51 nmol/l (276 pg/ml), norepinephrine/dihydroxyphenylglycol (DHPG) ratio greater than 1.09, or dopa greater than 35.53 nmol/l (7,000 pg/ml), in 30 of 39 patients with pheochromocytoma (sensitivity 77%) and 1 of 74 patients without pheochromocytoma (specificity 99%). Results of the glucagon test were abnormal (norepinephrine greater than 11.83 nmol/l [2,000 pg/ml] or more than threefold increase from baseline) in 25 of 31 patients with pheochromocytoma (sensitivity 81%) and 0 of 72 patients without pheochromocytoma (specificity 100%). Results of the clonidine test were abnormal (after clonidine norepinephrine greater than 2.96 nmol/l [500 pg/ml] or less than 50% decrease from baseline) in 29 of 30 patients with pheochromocytoma (sensitivity 97%) and in 7 of 30 patients without pheochromocytoma (specificity 67%). Very high baseline levels of catechols therefore indicated the presence of pheochromocytoma, but there were several false-negative results when normal levels were obtained. The glucagon test alone was highly specific but not sensitive, and the clonidine test was highly sensitive but less specific.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
Clin. Chem.Home page
K. L. Brain, J. Kay, and B. Shine
Measurement of Urinary Metanephrines to Screen for Pheochromocytoma in an Unselected Hospital Referral Population
Clin. Chem., November 1, 2006; 52(11): 2060 - 2064.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. S. Goldstein, G. Eisenhofer, J. A. Flynn, G. Wand, and K. Pacak
Diagnosis and Localization of Pheochromocytoma
Hypertension, May 1, 2004; 43(5): 907 - 910.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Eisenhofer, D. S. Goldstein, M. M. Walther, P. Friberg, J. W. M. Lenders, H. R. Keiser, and K. Pacak
Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2656 - 2666.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. S. Goldstein, G. Eisenhofer, and I. J. Kopin
Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 800 - 811.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. W. M. Lenders, K. Pacak, M. M. Walther, W. M. Linehan, M. Mannelli, P. Friberg, H. R. Keiser, D. S. Goldstein, and G. Eisenhofer
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
JAMA, March 20, 2002; 287(11): 1427 - 1434.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
K. Pacak, W. M. Linehan, G. Eisenhofer, M. M. Walther, and D. S. Goldstein
Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma
Ann Intern Med, February 20, 2001; 134(4): 315 - 329.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
E. Grossman and F. H. Messerli
High Blood Pressure: A Side Effect of Drugs, Poisons, and Food
Arch Intern Med, March 13, 1995; 155(5): 450 - 460.
[Abstract] [PDF]


Home page
HypertensionHome page
M. Hamada, Y. Shigematsu, M. Mukai, Y. Kazatani, T. Kokubu, and K. Hiwada
Blood Pressure Response to the Valsalva Maneuver in Pheochromocytoma and Pseudopheochromocytoma
Hypertension, February 1, 1995; 25(2): 266 - 271.
[Abstract] [Full Text]


Home page
JAMAHome page
H. R. Keiser
Surreptitious Self-administration of Epinephrine Resulting in 'Pheochromocytoma'
JAMA, September 18, 1991; 266(11): 1553 - 1555.
[Abstract] [PDF]